DOI: 10.1097/01.COT.0000365566.33554.1f

,  

Issn Print: 0276-2234

Publication Date: 2009/12/10


Print

Shakeup at CTRC Puts Ian Thompson at Helm: Challenges: Keeping, Recruiting Research Talent; Financing New Sources of Income; Regaining NCI Comprehensive Cancer Center Designation

Robert H. Carlson

    loading  Checking for direct PDF access through Ovid

Excerpt

San Antonio's Cancer Treatment and Research Center (CTRC) at the University of Texas Health Science Center now has its third new leader in five years: Ian M. Thompson, Jr., MD, well known as principal investigator of the Prostate Cancer Prevention Trial, as well as numerous other national and international urology trials.
Dr. Thompson, Professor and Chair of the university's Department of Urology until appointed CTRC Interim Director in October, succeeds Tyler Curiel, MD, Professor of Hematology and Medical Oncology and the CTRC's Executive Director since 2007.
Keeping and recruiting research talent and financing new sources of income for the CTRC are two immediate tasks for Dr. Thompson. In 2007, when the CTRC merged with the University of Texas Health Science Center at San Antonio, changes in the direction the center was taking caused an exodus of research talent and a drop in philanthropic income.
The restructure of the executive team brings two other new members to the executive team. Thomas J. Slaga, PhD, Professor of Pharmacology at the Health Science Center, becomes the CTRC's Interim Deputy Director; and Susan L. Mooberry, PhD, Professor of Pharmacology, with cross appointments in Biochemistry and Medicine, is the new Interim Director for the CTRC's Institute for Drug Development (IDD), succeeding Francis J. Giles, MB, MD, who remains on the faculty as Professor of Hematology and Medical Oncology.
    loading  Loading Related Articles